
Pomerantz LLP Launches Investigation into SELLAS Life Sciences
A 13.15% drop in SELLAS Life Sciences stock has triggered a formal investigation by Pomerantz LLP, as shareholders question the company’s transparency regarding critical clinical trial data for its experimental drug, Galinpepimut-S, following the milestone 80th patient death recorded in August.























